Skip to content

Evaluation of TaiHao Breast Ultrasound Diagnosis Software RN-CES Descartes

Evaluation of TaiHao Breast Ultrasound Diagnosis Software (Plan for Partial Modification of Diagnostic Performance)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05792475
Enrollment
3
Registered
2023-03-31
Start date
2023-01-30
Completion date
2023-11-30
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Diseases

Brief summary

A standard of truth SOT is determined based on the interpretation results of the case data by interpretation experts, and the SOT is compared with the detection results of this program's function for detecting suspected breast cancer (CADe function). Estimate the detectability of the CADe function by comparing.

Interventions

DIAGNOSTIC_TESTDefine Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software

TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.

Sponsors

TaiHao Medical Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

* Female patients aged 20 to 69, including those with and without breast lesions.

Exclusion criteria

* Have a pacemaker or prosthetic valve. * A post-surgery follow-up patient.

Design outcomes

Primary

MeasureTime frameDescription
The average performance of the 4 machines, in terms of sensitivity for detecting suspicious breast cancer, is not inferior to Siemens performance.1 weekThe average of 4 types of machines (Canon Aplio i800, GE Logiq E10, GE Invenia ABUS, Fuji ARIETTA 60) performance compared to Siemens performance which was submitted to PMDA last time.

Secondary

MeasureTime frameDescription
The performance of each of the 4 machines, in terms of sensitivity for detecting suspicious breast cancer, is not inferior to Siemens' performance.1 weekEach machine (Canon Aplio i800, GE Logiq E10, GE Invenia ABUS, Fuji ARIETTA 60) performance compared to Siemens performance which was submitted to PMDA last time.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026